微门户首页  新闻  讨论区  活动  博客  求职招聘  行业报告  圈内成员  供应   
已读[39] 发布: 2014/09/19 03:59:31
Medical Xpress Bivalirudin and heparin are two anticoagulant options for patients undergoing coronary stenting for ischemic heart disease. Bivalirudin, a newer anticoagulant, has been touted as being as effective as generic heparin , but with nearly half the rate of ... and more »
已读[40] 发布: 2014/09/19 03:59:26
Asian Scientist Magazine “For many years the use of low molecular weight heparin to treat such women has been widely accepted, despite limited research into its effectiveness,” says co-author Professor Bill Hague from the University of Adelaide's Robinson Research Institute.
已读[40] 发布: 2014/09/19 03:59:18
TCTMD Results of a prespecified subanalysis of the EUROMAX trial presented Saturday at TCT 2014 show bivalirudin matches heparin plus glycoprotein IIb/IIIa inhibitor (GPI) use with regard to residual ST-segment deviation. The findings reflect “comparable ... and more »
已读[40] 发布: 2014/09/19 03:59:13
Monthly Prescribing Reference Hospira has announced a voluntary nationwide user-level recall of one lot of Heparin Sodium, 1,000 USP Heparin Units/500mL (2 USP Hepa...
已读[37] 发布: 2014/09/19 03:59:08
In-PharmaTechnologist.com The US Food and Drug Administration (FDA) gave details of the recall on its website earlier today, explaining that the affected lot was shipped to pharmacies between June and August this year. “This action is due to one confirmed customer report of ...
已读[38] 发布: 2014/09/19 03:59:02
AAP News (subscription) One lot of heparin sodium injection is being recalled due to the presence of a foreign particle in one unit. Hospira Inc., of Lake Forest, Ill....
已读[37] 发布: 2014/09/19 03:58:57
Medscape WASHINGTON, DC — US cardiologists attending TCT 2014 finally got a first-hand look at the Chinese BRIGHT trial, heralded as the first randomized trial to compar...
已读[640] 发布: 2014/09/03 02:49:12
 过去一年,诺华深陷代文(Diovan)造假丑闻及专利悬崖,心血管新药serelaxin也因安全性问题被FDA和欧盟双双拒之门外。此次,诺华携心衰药LCZ696重磅数据凯旋归来,该药里程碑III期疗效和安全性超越临床标准药物依那普利。业界预测,LCZ696将挑战市面最成功药物,而且未来数年,LCZ696将无对手,该药将偿还诺华在心血管领...
已读[449] 发布: 2014/08/29 09:28:30
 心血管疾病是在全球引起死亡的最大杀手,每年导致750万人死亡。据世界卫生组织数据预测,到2030年,因心血管疾病死亡人数估计将会达到2500万。血栓(动脉和静脉)事件是心血管疾病的主要并发症,如果没有适当的处理,将具有致命性。   新治疗方案发挥效应   目前的抗血栓药物分为3类:血小板聚集抑制剂(PA...
已读[219] 发布: 2014/07/22 08:49:34
万脉舒与葛兰素史克原研产品速碧林在招标价格方面相差无几,几乎是国内普通的低分子肝素制剂价格的2倍以上。我们预计未来几年万脉舒仍将在肝素制剂市场保持领军地位...
« 上一页  |   查看结果1341-1350共2625   |  下一页 »



最新报告


求职招聘